Final APEX Phase 1b Clinical Results for Kodiak's KSI-101 in Macular Edema Secondary to Inflammation to be Presented at Angiogenesis 2026
Kodiak Sciences Inc (KOD)
Last kodiak sciences inc earnings: 11/12 05:30 am
Check Earnings Report
Company Research
Source: PR Newswire
PALO ALTO, Calif., Feb. 4, 2026 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a precommercial retina focused biotechnology company committed to researching, developing and commercializing transformative therapeutics, announced today participation at the virtual Angiogenesis (Angiogenesis, Exudation, and Degeneration) annual meeting on February 7, 2026.Dr. Sumit Sharma, retina and uveitis specialist at the Cole Eye Institute, will present first-time end-of-study clinical results, including Week 24 data, from the Phase 1b APEX study in patients with macular edema secondary to inflammation (MESI).Presentation title: Bispecific Trap-antibody Inhibiting Interleukin-6 and Vascular Endothelial Growth Factor (KSI-101): Phase 1b APEX Study in Patients with Macular Edema Secondary to Inflammation (MESI)Time: 5:15 PM ESTThe presentation will be posted at the start of the event on the "Events and Presentations" section of Kodiak's website at http://ir.kodiak.com/."This year's Angiogenesis m
Show less
Read more
Impact Snapshot
Event Time:
KOD
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
KOD alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
KOD alerts
High impacting Kodiak Sciences Inc news events
Weekly update
A roundup of the hottest topics
KOD
News
- Kodiak Sciences (NASDAQ:KOD) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $38.00 price target on the stock.MarketBeat
- Final APEX Phase 1b Clinical Results for Kodiak's KSI-101 in Macular Edema Secondary to Inflammation to be Presented at Angiogenesis 2026 [Yahoo! Finance]Yahoo! Finance
- Kodiak Sciences: A Stellar Move [Seeking Alpha]Seeking Alpha
- Kodiak Sciences (NASDAQ:KOD) had its "buy" rating reaffirmed by analysts at HC Wainwright.MarketBeat
- 3 Small-Cap Blend Mutual Funds With Strong Growth Potential [Yahoo! Finance]Yahoo! Finance
KOD
Earnings
- 11/13/25 - Miss
KOD
Sec Filings
- 12/19/25 - Form SCHEDULE
- 12/19/25 - Form 4
- 12/18/25 - Form 8-K
- KOD's page on the SEC website